{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:14:22Z","timestamp":1780452862479,"version":"3.54.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>A 71-year-old man was diagnosed with prostate cancer in 2012. After treatment with hormone, chemo, and combinations subsequently, the baseline prostate-specific membrane antigen PET scan revealed 130+ nodal and osseous metastatic lesions. After 4 doses of pluvicto, a partial response was appreciated. However, new intense prostate-specific membrane antigen avid hepatic lesions occupied around 30% of the liver with poorly differentiated metastatic prostate cancer 55 days after the last dose of pluvicto and markedly elevated prostate-specific antigen. This case highlights the need for vigilant monitoring and alternative treatment strategies.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005789","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T20:00:14Z","timestamp":1740513614000},"page":"523-524","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Intense Prostate-specific Membrane Antigen Avid Hepatic Metastatic Lesions Shortly After Finishing 6 Cycle Pluvicto Treatment"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9678-5468","authenticated-orcid":false,"given":"Xiaofei","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hogan","sequence":"additional","affiliation":[{"name":"West Virginia University Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kody","family":"Heubach","sequence":"additional","affiliation":[{"name":"Department of Pathology, West Virginia University, Morgantown, WV"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"R1-20250613","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"R2-20250613","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis","year":"2019","journal-title":"Eur Urol"},{"key":"R3-20250613","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"R5-20250613","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad Berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J Nucl Med"},{"key":"R6-20250613","first-page":"23","article-title":"Therapeutic outcomes of (177)Lu-PSMA targeted therapy in patients with metastatic castration-resistant prostate cancer: a single-center study","volume":"11","author":"Mirshahvalad","year":"2023","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"R7-20250613","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3390\/biom11081099","article-title":"Response assessment and prediction of progression-free survival by 68Ga-PSMA-11 PET\/CT based on tumor-to-liver ratio (TLR) in patients with mCRPC undergoing 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"Khreish","year":"2021","journal-title":"Biomolecules"},{"key":"R8-20250613","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2967\/jnumed.120.256263","article-title":"Mechanisms of resistance to prostate-specific membrane antigen-targeted radioligand therapy in a mouse model of prostate cancer","volume":"62","author":"Stuparu","year":"2021","journal-title":"J Nucl Med"},{"key":"R9-20250613","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2024.42.4_suppl.175","article-title":"Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment","volume":"42","author":"Muniz","year":"2024","journal-title":"J Clin Oncol"},{"key":"R10-20250613","article-title":"Prevalence of intra-patient inter-metastatic heterogeneity in mCRPC patients based on triple-tracer PET imaging: the 3TMPO study","volume":"41","author":"Pouliot","year":"2023","journal-title":"Genitourin Cancer Prostate Testicular Penile"},{"key":"R11-20250613","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bju.15621","article-title":"The triple-tracer strategy against metastatic prostate cancer (3TMPO) study protocol","volume":"130","author":"Pouliot","year":"2022","journal-title":"BJU Int"},{"key":"R12-20250613","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms23031046","article-title":"Impact of androgen receptor activity on prostate-specific membrane antigen expression in prostate cancer cells","volume":"23","author":"Sommer","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T12:00:33Z","timestamp":1749816033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005789"}},"subtitle":["Challenging and Reflects"],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005789","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"2024-07-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}